Immunotherapy Triggers Release of Mitochondrial DNA and Trips Alarm – Genetic Engineering & Biotechnology News (press release)
Genetic Engineering & Biotechnology News (press release) |
Immunotherapy Triggers Release of Mitochondrial DNA and Trips Alarm
Genetic Engineering & Biotechnology News (press release) Now, a group of researchers at UT Southwestern Medical Center report on their new finding that describe how cancer immunotherapy causes stressed tumor cells to release their mitochondrial DNA into nearby immune cells, triggering a host alert system. |
FierceBiotech |
Regenxbio to buy battered Dimension for gene therapies
FierceBiotech Regenxbio has penned a deal to acquire Dimension Therapeutics. The takeover will see Regenxbio pay about $86 million to add two of early-stage gene therapies to its pipeline. Rockville, Maryland-based Regenxbio swooped on Dimension to gain the … RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy CompaniesXconomy Regenxbio bags one of its gene therapy vector partners, buying out a struggling DimensionEndpoints News Rockville biotech buys Cambridge gene therapy firm for $86MWashington Business Journal Genetic Engineering & Biotechnology News –BioPharma Dive all 23 news articles » |
FierceBiotech |
Regenxbio to buy battered Dimension for gene therapies
FierceBiotech Regenxbio has penned a deal to acquire Dimension Therapeutics. The takeover will see Regenxbio pay about $86 million to add two of early-stage gene therapies to its pipeline. Rockville, Maryland-based Regenxbio swooped on Dimension to gain the … RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy CompaniesXconomy Regenxbio bags one of its gene therapy vector partners, buying out a struggling DimensionEndpoints News Rockville biotech buys Cambridge gene therapy firm for $86MWashington Business Journal Genetic Engineering & Biotechnology News –BioPharma Dive all 23 news articles » |
|
Dosing underway in Sangamo’s early-stage study of gene therapy SB-525 in hemophilia A
Seeking Alpha The first patient has been treated in a Phase 1/2 clinical trial, Alta, assessing Sangamo Therapeutics’ (NASDAQ:SGMO) gene therapy candidate SB-525. The open-label dose-ranging study will evaluate the safety and tolerability of SB-525 in 20 adults with … Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 …Markets Insider |
|
Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 …
Markets Insider 25, 2017 /PRNewswire/ — Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced that the first patient received treatment in the Phase 1/2 clinical trial (“the Alta trial”) evaluating SB-525, an investigational gene … |
Endpoints News |
Regenxbio bags one of its gene therapy vector partners, buying out a struggling Dimension
Endpoints News Gene therapy player Regenxbio $RGNX has struck a deal to buy the struggling Dimension Therapeutics $DMTX after a setback in the clinic earlier this year brutally hammered the biotech’s market cap down to only $30 million. Regenxbio has agreed to buy … REGENXBIO to Acquire Dimension TherapeuticsNasdaq |